Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Evogliptin (5mg) + Metformin (1000mg) Tablet
Therapeutic Category
Antidiabetic, Cardiology, Diabetic
Dosage Form
Tablet
Packaging Type
Alu Alu
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Metfoam 1000 E Tablet containing Evogliptin and Metformin is used for the management of type 2 diabetes mellitus. It helps improve glycemic control and supports effective blood glucose management as part of a comprehensive diabetes care plan.
Evogliptin works as a DPP-4 inhibitor that enhances incretin activity and supports glucose-dependent insulin secretion, while Metformin helps reduce hepatic glucose production and improves insulin sensitivity, contributing to better blood sugar control.
The tablet is widely prescribed in diabetology and general medicine practice for patients requiring combination therapy for effective glycemic management, leading to consistent prescription demand.
With the increasing prevalence of diabetes and growing demand for advanced anti-diabetic therapies, this product offers strong business potential for retailers and distributors. Its combination formulation, established clinical efficacy, and steady market demand make it a reliable product for growth in the anti-diabetic segment.
Some patients may experience nausea, vomiting, diarrhea, abdominal discomfort, bloating, headache, dizziness, or loss of appetite. Rarely, pancreatitis, severe allergic reactions, liver function abnormalities, or lactic acidosis associated with Metformin may occur and require immediate medical attention.
Metfoam 1000 E Tablet is indicated for the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and single-drug therapy are insufficient to achieve adequate glycemic control. It helps lower fasting and postprandial blood glucose levels and supports long-term diabetes management.
This medicine should be used strictly under medical supervision. Regular monitoring of blood glucose levels, kidney function, and liver function is recommended during treatment. Use cautiously in patients with kidney disease, liver impairment, heart failure, or conditions that increase the risk of lactic acidosis. Patients should continue following dietary recommendations, exercise routines, and other lifestyle modifications alongside therapy for optimal diabetes control.
Store in a cool, dry place below 25°C, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.
Composition : Glibenclamide I.P. 5mg + Metformin Hydrochloride I.P. 500mg + Pioglitazone Hydrochloride I.P. 15mg Tablets
Composition : Glimepiride (1mg) Tablet
Composition : Glimepiride (2mg) Tablet
Composition : Glimepiride 1mg + Metformin 500mg + Pioglitazone 15mg Bi-Layered Tablets
Composition : Glimepiride 2mg + Metformin Hydrochloride I.P. 500mg + Pioglitazone 15mg Bi-Layered Tablets
Composition : Gliclazide 80mg + Metformin Hydrochloride I.P. 500mg Tablets
Composition : LISINOPRIL 5 + AMLODIPINE 5 MG tablet
Composition : Aspirin 75mg + Rosuvastatin 10mg + Clopidogrel 75mg Tablet
Composition : Aspirin 75 mg + Rosuvastatin 20 mg + Clopidogrel 75 mg capsule
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.